|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC).|
This activity will improve the knowledge and competence of pharmacists about antiretroviral therapy (ART) regimens for patients living with HIV, including emerging agents and Pre-Exposure Prophylaxis (PrEP). Faculty will discuss individual patient factors, including racial disparities, to optimize ART and HIV care across the continuum.
The target audience for this activity includes pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients living with HIV or at risk for HIV. In addition, the target audience includes pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy. At the completion of this activity, the participant will be able to:
- Describe guideline-recommended ART regimens and appropriate counseling points for treatment-naïve patients, heavily treatment–experienced patients, and switch strategies for virologically suppressed patients living with HIV.
- Given patient cases, integrate individual patient factors such as drug–drug interactions, comorbidities, adverse events, pregnancy status, adherence, and dosing preferences when selecting optimal ART.
- Identify guideline recommendations and emerging strategies for Pre-Exposure Prophylaxis (PrEP).
- Discuss racial disparities in PrEP and strategies to improve engagement across the care continuum for HIV by combatting barriers to PrEP initiation and adherence.
- Recognize the potential place in therapy of recently approved and emerging pipeline agents for treatment of HIV.
Melissa Badowski, PharmD, MPH
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy, Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Anne R. Daniels, PharmD, BCPS, AAHIVP
Infectious Diseases Clinical Pharmacist, Department of Pharmacy
Froedtert and Medical College of Wisconsin
Jason Schafer, PharmD, MPH, BCPS, BCIDP, AAHIVP, FASHP
Professor and Vice Chair
Department of Pharmacy Practice
Jefferson College of Pharmacy, Thomas Jefferson University
Release Date: December 30, 2021
Expiration Date: December 30, 2022
This activity is jointly provided by ProCE, LLC and SIDP. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-280-H02-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Melissa Badowski has disclosed that she has no conflicts of interest to report. Anne Daniels has disclosed that she has received consulting fees from Theratechnologies. Jason Schafer has disclosed that he has received consulting fees from Merck, Theratechnologies, and ViiV.
This activity is supported by educational grants from Merck Sharp & Dohme Corp. and ViiV Healthcare.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.